Editor Brian Harrod Provides Comprehensive up-to-date news coverage, with aggregated news from sources all over the world from the Roundup Newswires Network
The idea that vitamin D supplements can reduce susceptibility to, and the severity of, Covid-19 is seductive – it offers a simple, elegant solution to a very complex and lethal problem. But analyses encompassing large European datasets suggest the enthusiasm for the sunshine vitamin may be misplaced.
Two still to be peer-reviewed papers looked at the link between vitamin D levels and Covid-19 and both reached the same conclusion: evidence for a direct link between vitamin D deficiency and Covid outcomes is lacking.
Face masks can be worn safely during intense exercise, and could reduce the risk of Covid-19 spreading at indoor gyms, preliminary findings suggests.
Scientists from the Monzino Cardiology Centre (CCM) in Milan and the University of Milan tested the breathing rate, heart rate, blood pressure and oxygen levels of six women and men on exercise bikes, with and without a mask.
Forty years after the mutant genes that cause the deadliest cancers were discovered, drugs that target them could be approved
In the early 1980s, Channing Der was just beginning his career as a scientist at Harvard Medical School when he happened upon a discovery that would change the course of cancer research. At the time, the holy grail of cancer biology was discovering so-called oncogenes – genetic switches that can turn a normal cell into a cancer cell – in the genomes of tumours. But while teams of scientists had thrown everything at it for the best part of a decade, their efforts had proved fruitless. One by one, they were beginning to accept that it might be a dead end.
Der found himself assigned to test 20 different genes that had been identified as possible oncogene candidates. His question was simple: did any of them actually exist in tumours in a form that was different from normal cells?
The arrival of Covid-19 vaccines promises a return to more normal life – and has created a global market worth tens of billions of dollars in annual sales for some pharmaceutical companies.
Among the biggest winners will be Moderna and Pfizer – two very different US pharma firms which are both charging more than $30 per person for the protection of their two-dose vaccines. While Moderna was founded just 11 years ago, has never made a profit and employed just 830 staff pre-pandemic, Pfizer traces its roots back to 1849, made a net profit of $9.6bn last year and employs nearly 80,000 staff.
Authorised vaccines that are modified to protect against new variants will not need to start a new approval process or undergo in-depth clinical studies, regulators in the UK, Australia, Canada, Singapore and Switzerland have said.
Manufacturers will need to provide “robust evidence that the modified vaccine produces an immune response, but time-consuming clinical studies that do not add to the regulatory understanding of a vaccine’s safety, quality or effectiveness would not be needed”, bringing the process into line with that already used for updated flu jabs.
Alongside data on the immune response, the vaccine manufacturer would also be expected to provide evidence showing the modified vaccine is safe and is of the expected quality. In addition, data from the original robust clinical trials and the ongoing studies on real-world use in millions of people could be used to support any decision by the regulators.
This approach is based on the tried and tested regulatory process used for seasonal flu vaccines, for which annual modifications are needed to match the strains circulating each year.
Our priority is to get effective vaccines to the public in as short a time as possible, without compromising on safety. Should any modifications to authorised Covid-19 vaccines be necessary, this regulatory approach should help to do just that.
The announcement today also demonstrates the strength of our international partnerships with other regulators and how our global work can help ensure faster access to life-saving vaccines in the UK and around the world.
While worrisome coronavirus variants identified in Brazil, South Africa, and California have mutations that might help them resist antibody treatments and vaccines, the immune system’s T cell responses to the variants are unaffected in recovered patients and in people who have received the Moderna Inc or Pfizer Inc/BioNTech vaccines, new data show.
Reuters: The T cells induced by vaccines can recognise pieces of the virus spike protein, while T cells induced by previous infection recognise multiple parts of the virus, including the spike and other proteins, said Alessandro Sette of the La Jolla Institute for Immunology.
“These pieces are largely not changed/mutated in the variants,” he explained. “This means that the T cell responses recognise the ‘ancestral’ sequence and the variants equally well.”
Coronavirus vaccines tweaked to deal with variants will be fast-tracked without compromising on safety or effectiveness, the UK’s regulator has said.
The approach will be similar to the regulatory process for the modified flu vaccine, to deal with new strains each year, with a brand new approval not required.
Countries with high levels of overweight people, such as the UK and the US, have the highest death rates from Covid-19, a landmark report reveals, prompting calls for governments to urgently tackle obesity, as well as prioritising overweight people for vaccinations.
About 2.2 million of the 2.5 million deaths from Covid were in countries with high levels of overweight people, says the report from the World Obesity Federation. Countries such as the UK, US and Italy, where more than 50% of adults are overweight, have the biggest proportions of deaths linked to coronavirus.
Northern Ireland’s deputy first minister, Michelle O’Neill, has unveiled a cautious five-step plan to ease the region’s Covid-19 lockdown. The plan has no hard dates and will be led by data, notably the reproductive rate of the virus, O’Neill told the Stormont assembly on Tuesday.
The coronavirus variant originally found in Manaus in Brazil and detected in six cases in the UK was able to infect 25% to 61% of the people in the Amazonian city who might have expected to be immune after a first bout of Covid, researchers say.
The extent to which P1 can evade the immune system, and potentially vaccines, emerged as the UK health secretary said the hunt for one person who tested positive for P1 – but did not leave contact details – had narrowed to 379 households in the south-east of England.
Authorities in Germany and France are under pressure to come up with creative solutions to shift the AstraZeneca vaccine at higher speed in order to avoid a pile-up of unused doses over the coming weeks.
On Monday, France’s medical regulator reversed its advice not to use the AstraZeneca jab on over-65s, and Germany’s vaccination committee is coming under increasing pressure to follow suit or even scrap prioritisation altogether.
Scientists have warned that emerging data on long Covid in children should not be ignored given the lack of a vaccine for this age group, but cautioned that the evidence describing these enduring symptoms in the young is so far uncertain.
Recently published data from the Office for National Statistics (ONS) has caused worry. The data suggest that 13% of under 11s and about 15% of 12- to 16-year-olds reported at least one symptom five weeks after a confirmed Covid-19 infection. ONS samples households randomly, therefore positive cases do not depend on having had symptoms and being tested.
Germany could soon authorise the use of the AstraZeneca vaccine for seniors after the head of the country’s vaccination committee said his body’s advice to give the Oxford-developed vaccine only to those under 65 had “somehow gone wrong”.
Unlike the European Medicines Agency or Britain’s MHRA, Germany’s Standing Committee on Vaccination (Stiko) last month recommended against the use of the AstraZeneca vaccine on seniors, citing a lack of conclusive trial data to prove its efficacy in that age group.
The prospects of vaccines failing to trigger immune responses are dismissed as remote by scientists. “If a vaccine has not been properly refrigerated that might pose problems but doctors take great care to ensure that doesn’t happen,” said Prof Helen Fletcher at the London School of Hygiene & Tropical Medicine. “Frankly the only other way to get a failed reaction is for the doctor to miss your arm – which isn’t likely.”
A single dose of the Pfizer vaccine can reduce asymptomatic infections by 75%, according to research that suggests the jab could substantially curtail transmission of the disease.
Doctors in Cambridge recorded the sharp fall in infections after 12 days of the first shot in an analysis of Covid tests performed on healthcare workers in the last two weeks of January.
Covax has delivered its first Covid-19 vaccine doses in a milestone for the ambitious programme that seeks to offset “vaccine nationalism” by wealthy countries and ensure poor ones do not wait years to start inoculating people.
An aircraft carrying 600,000 doses of the Oxford/AstraZeneca vaccine landed in Accra, the capital of Ghana, on Wednesday, where jabs will be administered to frontline health workers on Tuesday. Vaccine doses will arrive on Friday in Abidjan, Ivory Coast, and will be given from Monday.
Greece reported 1,424 new coronavirus cases on Saturday, as well as 23 further deaths.
This compares with 1,222 cases and 26 deaths last Saturday.
There have been more than 3.8 million confirmed Covid-19 cases on the African continent, and more than 100,000 fatalities.
The number is understood to be an underestimation, with the director of the Africa Centres for Disease Control and Prevention (CDC) saying last week that it was “definitely not counting all the deaths, especially in the second wave”.
Over 3.8 million confirmed #COVID19 cases on the African continent - with more than 3.3 million recoveries & 100,000 deaths cumulatively.
Israel is preparing itself to be split in half from next week, with the government creating a new privileged tier in society: the vaccinated.
Nearly 50% of the population who have chosen to be inoculated against Covid will be provided with a “green pass” a week after their second shot, as will those with presumed immunity after contracting the disease.
Human challenge trials for coronavirus are to begin in the UK, a world first in the global fight against Covid-19.
Healthy adult volunteers aged between 18 and 30 will be exposed to coronavirus in a controlled environment, to learn more about how their body reacts to the virus, how it is transmitted and how much of the virus is needed to cause infection.
There will continue to be plenty more data gaps because the Covid-19 strain simply behaves like all influenzas and mutates continuously
By the time you read this it will be out of date.
Why? Because every day we receive new data that causes us to rethink and rewrite our response to Covid-19, notably vaccine programs. This is good. I will explain.